Novomix 30 Flexpen (Insulin Aspart)

Insulin aspart binds to insulin receptors on muscle, fat and liver cells, activating a tyrosine‑kinase cascade that moves GLUT‑4 transporters to the cell surface. This accelerates glucose uptake from the bloodstream and suppresses hepatic glucose production, producing a rapid reduction in blood sugar after injection.

The dose of Novomix 30 Flexpen is individualized. A qualified prescriber determines the amount based on the patient’s current glucose levels, carbohydrate intake, body weight, renal function and overall treatment plan. Patients should follow the dosing instructions provided by their healthcare professional.

Insulin aspart is classified as pregnancy category B in many regions, meaning animal studies have not shown risk, but adequate human data are limited. It may be used during pregnancy or lactation when the benefits outweigh potential risks, but the decision should be made by a qualified obstetrician or endocrinologist.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Novomix 30 Flexpen (insulin aspart) has a similar onset of action to other rapid‑acting analogues such as insulin lispro and insulin glulisine. Clinical studies show comparable post‑prandial glucose reductions, but formulation differences, device convenience and individual patient response may influence the choice of product.

Novomix 30 Flexpen should be stored in a refrigerator at 2‑8 °C, protected from light and moisture. Do not freeze or shake the pen. Once in use, the pen can be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, after which it must be discarded.

The product is a prefilled FlexPen designed for subcutaneous injection. The user selects the prescribed dose using the pen’s dial, inserts the needle, and injects into the abdomen, thigh or upper arm. Injection technique and site rotation should follow the prescribing information to minimize lipodystrophy.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of hypoglycemia, have a source of fast‑acting carbohydrate available, and seek immediate medical attention for any signs of a severe allergic response.

Novomix 30 Flexpen is contraindicated in individuals with a known hypersensitivity to insulin aspart or any of the pen’s excipients. It should also be avoided in patients with severe hypoglycemia unawareness unless closely supervised, and in those for whom rapid‑acting insulin is not appropriate as determined by a qualified healthcare professional.